http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201891241-A1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2016-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EA-201891241-A1 |
titleOfInvention | 1,3,4-TIADIAZOLIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER |
abstract | A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Q may be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl or 6-fluoropyridazin-3-yl; R may be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluorosetidin-1-yl, 3-methoxyazetidin-1-yl or 3,3-difluoroazetidin-1-yl; May be hydrogen or fluorine; R may be hydrogen or methoxy and R may be methoxy, ethoxy or methoxymethyl; provided that if R is hydrogen, methoxy or trifluoromethoxy, then R is not hydrogen, and / or R is methoxymethyl. The compound of formula (I) can inhibit glutaminase, for example, GLS1. |
priorityDate | 2015-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 194.